Single Lung Transplant Surgery: Recovery Timeline
A typical 16-week recovery is divided into 4 phases. Open a phase for its goals, daily activities and warning signs.
Jump to a phase
Phases of recovery
Phase 1: ICU, Inpatient, and Early Post-Discharge Recovery (Weeks 1–4)
Goals:
- The transplanted lung is denervated — the nerve supply that normally coordinates cough, airway tone, and mucociliary clearance below the bronchial anastomosis has been severed. This is not a complication; it is an inevitable consequence of the transplant procedure, and it will not recover. The practical meaning of denervation is that you cannot rely on your transplanted lung to warn you that something is wrong the way your native lungs would. An infection brewing in the transplanted lung may not trigger a cough. Aspirated food or liquid may not provoke the reflex clearing response that would normally protect you. This is why home spirometry, regular surveillance bronchoscopy, and aggressive pulmonary hygiene are not optional — they are the substitute for the protective reflexes your transplanted lung has lost.
- Your immunosuppressive regimen consists of three medications working through different mechanisms to prevent your immune system from destroying the transplanted lung. The standard triple therapy includes tacrolimus (a calcineurin inhibitor that is the backbone of transplant immunosuppression), mycophenolate mofetil (an antimetabolite that suppresses lymphocyte proliferation), and prednisone (a corticosteroid that broadly dampens the immune response). Many centers use induction therapy with basiliximab or antithymocyte globulin at the time of transplant to provide intense immunosuppression while oral medications reach therapeutic levels.
- Tacrolimus requires trough level monitoring — a blood draw taken 12 hours after your last dose, typically before your morning dose. Levels are checked frequently in the first weeks, often daily during the inpatient stay and then two to three times weekly after discharge. The therapeutic window is narrow: too little and you risk rejection; too much and you risk nephrotoxicity, neurotoxicity (tremor, headache, and in severe cases posterior reversible encephalopathy syndrome), hypertension, and diabetes. Learning to take tacrolimus at exactly the same times every day, consistently with or without food as directed, is essential. The consequences of non-adherence are severe. Acute cellular rejection is most common in the first six months, and even a few missed doses during this period can trigger an episode that permanently damages the graft.
- Acute cellular rejection is most common in the first six months after lung transplant and is monitored through two complementary systems. Surveillance transbronchial biopsies are the gold standard — protocol bronchoscopies are typically performed at approximately 1 month, 3 months, 6 months, and 12 months after transplant, though many centers perform additional biopsies if there is clinical suspicion. Each bronchoscopy involves passing a flexible bronchoscope through the mouth or nose into the transplanted lung, where small tissue samples (biopsies) are taken from the airway wall and lung parenchyma. Bronchoalveolar lavage is performed simultaneously to evaluate for infection. The procedure is done under sedation and takes approximately 30 to 45 minutes. It is uncomfortable but not painful, and most patients tolerate it well after the first experience.
- Home spirometry is the second surveillance system and in many ways the more important one for day-to-day management. You will be provided with a portable handheld spirometer and instructed to perform daily measurements of your forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). These values should be recorded and reported to your transplant team according to their protocol — many centers use smartphone applications that transmit data directly. The critical threshold to understand is this: a sustained decline in FEV1 of more than 10 percent from your established personal best baseline triggers urgent evaluation. This decline could represent acute rejection, infection, airway anastomotic stricture, or the early stages of chronic lung allograft dysfunction. It may not cause symptoms that you notice, which is precisely why daily spirometry is so important. Your transplanted lung's denervated airways may not generate the dyspnea or cough that would normally alert you to trouble.
- Infection is the leading cause of death in the first year after lung transplant, and the transplanted lung's direct exposure to the environment makes it uniquely vulnerable among transplanted organs. Your prophylactic medication regimen addresses the three major categories of opportunistic infection. Valganciclovir prevents cytomegalovirus (CMV) reactivation — CMV can directly damage the transplanted lung and has been associated with accelerated development of chronic rejection. The duration of valganciclovir prophylaxis depends on the CMV serostatus of donor and recipient, with donor-positive/recipient-negative (D+/R-) patients at highest risk and receiving the longest prophylaxis, typically 12 months. Trimethoprim-sulfamethoxazole (TMP-SMX) prevents Pneumocystis jirovecii pneumonia (PJP), which can be fatal in immunosuppressed patients. Many lung transplant centers continue PJP prophylaxis indefinitely. Antifungal prophylaxis targets Aspergillus species, which can colonize the bronchial anastomosis and cause invasive disease. Inhaled amphotericin, itraconazole, or voriconazole are used depending on center protocol and patient risk factors.
- Behavioral infection prevention measures are the same rigorous precautions required after any solid organ transplant. Frequent thorough hand washing. Avoidance of sick contacts. Avoidance of crowds and enclosed public spaces in the first three months. Food safety: no raw or undercooked meat, fish, or eggs; no unpasteurized dairy; thorough produce washing. Avoidance of gardening without gloves, cat litter, bird droppings, and stagnant water. These precautions are most stringent early and are gradually relaxed, though a baseline level of vigilance remains permanent.
- Because your transplanted lung cannot cough effectively on its own below the anastomosis, active pulmonary hygiene is essential. Incentive spirometry should be used frequently — 10 repetitions every one to two hours while awake during the first two weeks. Directed cough techniques should be practiced: deep inspiration, brief hold, and a forceful cough while splinting the thoracotomy incision with a pillow. Some patients benefit from airway clearance devices such as oscillating positive expiratory pressure (PEP) devices or flutter valves, which help mobilize secretions from the small airways into larger airways where they can be cleared. Nebulized hypertonic saline may be used to improve secretion clearance.
- Early mobilization begins in the ICU. Sitting in a chair on the first postoperative day, standing and taking steps as soon as hemodynamically stable, and progressing to hallway walking during the inpatient stay. The goal during Phase 1 is not fitness but functional independence — the ability to perform basic activities of daily living, walk on flat surfaces, and manage stairs. Formal outpatient pulmonary rehabilitation begins after hospital discharge, typically within the first two to four weeks, and is a critical component of lung transplant recovery. Patients who were enrolled in pulmonary rehabilitation before transplant have a significant advantage because they understand exercise pacing, breathing techniques, and the effort required.
- One or more chest tubes are placed during surgery to drain the pleural space. Output is monitored for volume and character, and tubes are removed when output falls below threshold (typically less than 200 mL per 24 hours) and there is no significant air leak. After discharge, the thoracotomy incision should be kept clean and dry, inspected daily for signs of infection, and not submerged in water until fully healed. The posterolateral thoracotomy incision is large and crosses multiple muscle planes, so wound healing takes several weeks. Some patients experience seroma formation — a collection of fluid beneath the incision — which is usually managed conservatively but should be reported.
- Thoracotomy pain is among the most intense of any surgical incision. The intercostal nerves that run along the ribs are stretched, compressed, or transected during the procedure, and the resulting pain is sharp, position-dependent, and exacerbated by deep breathing and coughing — precisely the activities that are most important for pulmonary hygiene. Effective pain management is therefore not merely a comfort measure but a clinical necessity. Many centers use thoracic epidural catheters or paravertebral nerve blocks during the first 3 to 5 postoperative days, transitioning to oral multimodal analgesia. The oral regimen typically combines scheduled acetaminophen, gabapentin or pregabalin for neuropathic intercostal pain, and opioids with a defined taper. NSAIDs are avoided because renal function must be preserved for safe immunosuppressive management. Patients should understand that some degree of thoracotomy pain persists for weeks to months and that a minority develop chronic post-thoracotomy pain syndrome from intercostal nerve injury.
- Gastroparesis and gastroesophageal reflux are remarkably common after lung transplant, likely related to vagus nerve injury during the procedure and the effects of immunosuppressive medications. This is far more than a comfort issue. Aspiration of gastric contents into the transplanted lung — even microaspiration that occurs silently during sleep — has been convincingly associated with the development of chronic lung allograft dysfunction. Aggressive reflux management with proton pump inhibitors is standard, and some patients require prokinetic agents. Patients should be counseled to elevate the head of bed, avoid eating within 3 hours of lying down, and report new or worsening reflux symptoms promptly. Some centers perform routine esophageal pH monitoring or gastric emptying studies to identify patients at high aspiration risk, and in severe cases, surgical fundoplication may be recommended.
- FEV1 and FVC measurements (home spirometer, recorded and reported)
- Oxygen saturation at rest and with activity
- Temperature (report any fever above 38.0C)
- Sputum: amount, color, consistency (changes may indicate infection)
- Medication adherence confirmation (exact times)
- Pain level and adequacy of analgesia
- Thoracotomy wound inspection (photo for check-in)
- Fluid intake
- Reflux symptoms
- Exercise tolerance (distance walked, exertion level)
- Mood and energy level
Restrictions:
- No lifting heavier than 5 kg for the first 6 weeks (protects thoracotomy healing)
- No driving until transplant team clearance (typically 6-8 weeks)
- No submersion of wound in water until fully healed
- Strict medication adherence — never miss a dose, never adjust without team guidance
- Infection precautions as outlined above (most intensive in first 3 months)
- No live vaccines (lifelong)
- No NSAIDs (nephrotoxic; acetaminophen only for pain relief)
- No grapefruit or grapefruit juice (alters tacrolimus metabolism)
- No herbal supplements or OTC medications without transplant team approval
- Sun protection lifelong (immunosuppression significantly increases skin cancer risk)
- No smoking or secondhand smoke exposure (absolute — destroys the graft)
Call your care team if:
- Acute dyspnea or new oxygen requirement (rejection, infection, PE, or anastomotic complication)
- FEV1 decline of more than 10% from established baseline on home spirometry
- Fever above 38.5C with rigors, productive cough, or hemodynamic changes
- Hemoptysis (any amount — airway anastomotic concern until proven otherwise)
- Sudden chest pain with respiratory distress (pneumothorax, PE, or pleural complication)
- Signs of stroke: new focal deficit, speech difficulty, facial asymmetry
- Seizure or severe headache with visual changes (tacrolimus toxicity or PRES)
- Signs of sepsis: fever with confusion, tachycardia, hypotension
Phase 2: Pulmonary Rehabilitation and Graft Optimization (Weeks 5–8)
Goals:
- Formal outpatient pulmonary rehabilitation should be well underway during Phase 2 and should be pursued aggressively. Lung transplant rehabilitation differs from standard pulmonary rehabilitation in important ways. The transplanted lung is denervated, meaning that respiratory drive and airway responses are altered. However, the lung parenchyma itself functions normally — gas exchange, perfusion, and alveolar mechanics are those of a healthy donor organ. The goal of rehabilitation is to rebuild the skeletal muscle deconditioning, cardiovascular fitness, and functional capacity that deteriorated during months or years of end-stage lung disease.
- Exercise prescription for lung transplant patients uses rate of perceived exertion (RPE) rather than relying solely on heart rate or oxygen saturation targets, because the interaction between the denervated transplanted lung and the innervated cardiovascular system creates variable physiologic responses. Walking should progress from the short distances of Phase 1 to sustained walking of 20 to 40 minutes. Resistance training for both upper and lower extremities is introduced, with particular attention to the muscles of the upper back and shoulder that may be weakened by the posterolateral thoracotomy incision and the deconditioning of pre-transplant illness. Balance and flexibility exercises complement the strength and endurance components.
- Patients who commit to aggressive rehabilitation after single lung transplant can achieve meaningful functional recovery, though the ceiling is lower than bilateral transplant because the native lung (with its underlying disease) remains and limits overall pulmonary reserve. For patients transplanted for emphysema, the retained hyperinflated native lung may compress the graft to some degree, limiting the FEV1 that can be achieved. For patients transplanted for fibrosis, the retained stiff native lung contributes restrictive physiology. Understanding this limitation helps set realistic expectations while still encouraging maximum effort in rehabilitation.
- Daily FEV1 and FVC measurements continue as a non-negotiable part of post-transplant life. By Phase 2, you should have established a baseline personal best FEV1 against which all future measurements are compared. The critical alarm threshold remains a decline of more than 10 percent from this baseline, but even smaller declines (5 to 10 percent) sustained over several days warrant notification to your transplant team. Spirometry trends over time are more informative than single measurements, which can vary with technique, time of day, and transient airway inflammation. Performing measurements at the same time each day under consistent conditions improves reliability.
- Corticosteroid-induced osteoporosis is one of the most consequential long-term side effects of transplant immunosuppression. Bone loss begins within the first weeks of corticosteroid therapy and is most rapid in the first 6 to 12 months. The thoracotomy places mechanical demands on the rib cage that make fracture prevention particularly relevant. Calcium and vitamin D supplementation should be started if not already in place, and many transplant programs initiate bisphosphonate therapy (such as alendronate or zoledronic acid) within the first month of transplant based on bone density assessment. Weight-bearing exercise during pulmonary rehabilitation provides additional bone protection.
- Immunosuppressed transplant recipients have a dramatically increased risk of skin cancer, particularly squamous cell carcinoma, which is not only more common but also more aggressive in immunosuppressed patients. Sun protection must begin during this phase if not already established and must continue lifelong. This means broad-spectrum sunscreen (SPF 30 or higher) applied to all exposed skin when outdoors, protective clothing including wide-brimmed hats, and avoidance of deliberate sun exposure and tanning. Annual full-body skin examinations by a dermatologist should be established as part of the long-term transplant surveillance calendar.
Restrictions:
- Lifting restrictions easing (progress to 10 kg by week 6-8 if wound healing permits)
- Continue all immunosuppression exactly as prescribed
- Continue infection precautions (easing slightly but still significant)
- No NSAIDs (lifelong)
- No grapefruit (lifelong)
- Sun protection (lifelong)
- No new medications or supplements without transplant team approval
- No smoking or secondhand smoke (absolute, lifelong)
Phase 3: Expanding Independence and Functional Recovery (Weeks 9–12)
Goals:
- By weeks 9 to 12, most single lung transplant recipients have achieved a substantial improvement in functional capacity compared to their pre-transplant state. Walking distances of 30 to 60 minutes are realistic for many patients. Light aerobic exercise — stationary cycling, elliptical training, gentle swimming (if wounds are fully healed and team approves) — can be introduced. Resistance training continues to rebuild muscle mass lost during the deconditioning of end-stage lung disease and the catabolic effects of corticosteroids.
- Driving clearance is typically granted during this phase, contingent on adequate pain control (off opioids), physical ability to perform emergency maneuvers, and transplant team approval. Light work return is possible for desk-based occupations, though the frequency of medical appointments (labs, clinic visits, upcoming bronchoscopy) requires schedule flexibility. Patients whose pre-transplant occupation involved heavy physical labor, high infection exposure (healthcare, childcare, construction), or environmental irritant exposure should discuss long-term occupational planning with their transplant team.
- Infection prevention measures continue but with somewhat less social restriction than the immediate postoperative period. Hand hygiene, food safety, and avoidance of sick contacts remain important. Mask-wearing in crowded enclosed spaces is recommended, particularly during respiratory illness seasons, but the degree of restriction is calibrated by the transplant team based on the patient's immune status and local epidemiology.
- Steroid taper should be progressing per center protocol. As prednisone doses decrease, patients may experience transient fatigue, joint aches, and mood changes as the adrenal-pituitary axis readjusts. These symptoms are temporary and should not prompt patients to increase their steroid dose on their own. Some centers aim for complete steroid withdrawal in low-risk patients; others maintain a low-dose regimen (5 mg daily) indefinitely.
Phase 4: Lifelong Transplant Living (Weeks 13–16)
Get this timeline as a daily plan →Free tool: Build a Single Lung Transplant Surgery recovery timeline with your own dates — no signup needed for the preview.